Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CTNU | ISIN: US68403P2039 | Ticker-Symbol: OJU1
Tradegate
05.06.25 | 19:29
1,855 Euro
-0,88 % -0,017
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ORAMED PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ORAMED PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8331,90515:53
1,8331,90515:53

Aktuelle News zur ORAMED PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.05.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report6
28.04.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report3
ORAMED PHARMACEUTICALS Aktie jetzt für 0€ handeln
28.04.Oramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical5
28.04.Oramed investiert 36,9 Millionen US-Dollar in Alpha Tau Krebstherapie19
28.04.Alpha Tau Medical Ltd.: Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals2
28.04.Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical257Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies...
► Artikel lesen
27.03.ORAMED PHARMACEUTICALS INC. - 10-K, Annual Report20
04.03.Oramed macht Fortschritte bei oralem Insulin, plant Phase-3-Studie und Dividende30
27.02.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report4
26.02.Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock25
11.02.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report16
11.02.Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology32
11.02.Oramed announces spinoff of protein drug technology37
22.01.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report12
21.01.Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 20253
03.01.ORAMED PHARMACEUTICALS INC. - 8-K, Current Report6
17.12.24ORAMED PHARMACEUTICALS INC. - 8-K, Current Report19
07.10.24Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt293NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...
► Artikel lesen
26.06.24Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders312Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:...
► Artikel lesen
26.06.24Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock269NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1